1. Senseonics is like **Dexcom**, but for a continuous glucose monitor that's **implanted under the skin and works for up to six months**.

2. Think of it as an **Apple Watch for diabetes**, but instead of wearing it, a tiny glucose sensor is **implanted and lasts for half a year**.

3. It's a medical device company similar to **Medtronic**, but focused on a unique **long-term implantable continuous glucose monitor**.

• Eversense: An implantable continuous glucose monitoring (CGM) system that measures glucose levels via an under-the-skin sensor, a smart transmitter, and a mobile app.
• Eversense XL: An implantable continuous glucose monitoring (CGM) system that measures glucose levels via an under-the-skin sensor, a smart transmitter, and a mobile app.

The major customer and global commercial partner for Senseonics Holdings is:

• Ascensia Diabetes Care

Ascensia Diabetes Care is a private company and is the exclusive global commercial partner responsible for the sales and distribution of Senseonics' Eversense continuous glucose monitoring (CGM) systems.

Timothy T. Goodnow, PhD, President & CEO

Timothy T. Goodnow joined the Senseonics Board of Directors in December 2010 and was named President & CEO in March 2011. He has been instrumental in commercializing the Eversense continuous glucose monitoring (CGM) systems in Europe and the U.S.. Prior to Senseonics, Dr. Goodnow served as Vice President of Technical Operations at Abbott Diabetes Care and held executive positions at TheraSense, Verax Biomedical, Dade Behring, and Baxter Healthcare. TheraSense, where he held an executive position, was acquired by Abbott. He earned his PhD and Bachelor of Science degree in Chemistry at the University of Miami.

Frederick T. Sullivan, Chief Financial Officer, Secretary and Treasurer

Frederick T. Sullivan was appointed Chief Financial Officer of Senseonics Holdings, Inc. effective September 1, 2022. Prior to this role, he served as the Company's Vice President of Finance since October 2020. Mr. Sullivan's experience before joining Senseonics includes serving as a Principal at Hike Financial and Chief Financial Officer of RoosterBio. Inc.. He also held positions as Treasurer and Controller within Senseonics and progressively advanced through various finance roles at the company. He is a certified public accountant and holds a Masters of Business Administration from the University of Maryland - Robert H. Smith School of Business and a Bachelor of Science in accounting from Salisbury University - Perdue School of Business.

Mukul Jain, PhD, Chief Operating Officer

Mukul Jain is the Chief Operating Officer at Senseonics, responsible for overseeing Quality, Regulatory, Product Development, and Global Operations, which includes manufacturing and supply chain. Before joining Senseonics, Dr. Jain spent 13 years at Medtronic, where he worked on active implantable devices in the CRDM and Neuromodulation sectors. He managed the development of Neurostimulator systems in spinal cord stimulation and sacral nerve stimulation and also worked at Medtronic Energy and Components Center developing critical components for implantable devices.

Francine R. Kaufman, M.D., Chief Medical Officer

As Chief Medical Officer, Dr. Francine R. Kaufman focuses on driving the innovation platform and clinical value proposition of the Eversense CGM system. She is a leading endocrinologist with nearly 40 years of experience in diabetes care. Prior to her role at Senseonics, Dr. Kaufman served as Chief Medical Officer and Vice President of Global Clinical, Regulatory and Medical Affairs at Medtronic Diabetes from 2009 to January 2019.

Brian Hansen, Chief Commercial Officer

Brian Hansen was appointed as Senseonics' Chief Commercial Officer in January 2026, having previously served as Ascensia's President of CGM since February 2024. He possesses over 30 years of commercial experience across the medical device, life sciences, and diagnostic industries. Before his time at Ascensia, Mr. Hansen was Executive Vice President and Chief Commercial Officer at Tandem Diabetes Care starting in January 2016, and held key leadership positions at Adaptive Biotechnologies, Novartis, Gen-Probe, and Fisher Scientific.

The key risks for Senseonics Holdings (SENS) are primarily centered around its financial viability, the adoption and commercialization of its continuous glucose monitoring (CGM) systems, and intense competition in the medical technology sector.

1. Financial Viability and Going Concern: Senseonics Holdings faces significant financial distress, with the company itself having expressed "substantial doubt about its ability to continue as a going concern" due to recurring losses and uncertainty regarding its liquidity. The company experiences high sales and marketing expenses and other operating costs, contributing to ongoing negative free cash flow and significant share dilution. Reports indicate a limited cash runway, estimated to be between 9 and 13 months without additional capital raises.
2. Adoption and Commercialization Challenges: A major risk is the adoption and retention of patients for its Eversense CGM systems, particularly the Eversense 365. Despite the product's unique long-term wear, numerous barriers hinder adoption, including the necessity of a medical procedure for insertion and prior authorization, which can deter potential patients. The company has acknowledged an anemic user base growth, hampered by these adoption challenges. Furthermore, Senseonics is in the process of re-taking full commercial control of its products from its distribution partner, Ascensia Diabetes Care, a transition that requires building new sales and marketing infrastructure and securing additional funding, introducing execution risks.
3. Intense Competitive Landscape: Senseonics operates in a highly competitive global CGM market where its products compete against kits from other manufacturers. While Eversense offers advantages like extended duration and implantability, competitors often provide easier-to-start solutions that do not require an office visit or a medical procedure, posing a significant challenge to customer acquisition and retention. Despite the overall growth of the CGM market, Senseonics remains a relatively small player.

The addressable market for Senseonics Holdings' continuous glucose monitoring (CGCGM) systems, such as Eversense, encompasses significant global and U.S. markets.

Globally, the continuous glucose monitoring market was valued at approximately USD 13.86 billion in 2025 and is projected to grow to about USD 15.52 billion in 2026. Another estimate indicates the global market size was USD 13.4 billion in 2025 and is projected to reach USD 15.5 billion in 2026. This market is anticipated to expand further, with projections reaching USD 33.61 billion by 2034 or USD 41.4 billion by 2033.

In the United States, the continuous glucose monitoring market is substantial. It was estimated at USD 6.28 billion in 2025 and is projected to reach USD 7.43 billion in 2026. The U.S. market is expected to continue its growth trajectory, potentially reaching USD 17.16 billion by 2031. North America held a significant share of the global market, accounting for 44.6% in 2025. Senseonics Holdings itself indicates that the U.S. total addressable market is more than $20 billion, with the market remaining significantly underpenetrated.

For Europe, Senseonics noted that the European approval for Eversense 365 expands its total addressable market by over 30 million patients living with diabetes in the European Union.

Senseonics Holdings, Inc. (SENS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Increased Adoption and Reimbursement of Eversense 365 (E365): A primary driver of revenue growth is the continued and expanding adoption of the Eversense 365 continuous glucose monitoring (CGM) system in the U.S. and internationally. The company expects full-year 2025 global net revenue to be approximately $34-38 million, primarily driven by the rollout of Eversense 365 to U.S. patients. This growth is supported by positive Centers for Medicare & Medicaid Services (CMS) reimbursement for the one-year CGM, effective January 1, 2025, which is considered a significant milestone for patient access. Senseonics aims to approximately double its global patient base in 2025.
2. Enhanced Commercialization Strategy and Direct-to-Consumer (DTC) Marketing: Senseonics is transitioning its commercialization and distribution efforts from Ascensia to an in-house model, which is anticipated to lead to higher revenue and improved gross margins. This strategic shift involves taking over the full sales and marketing infrastructure, including in Europe. Aggressive direct-to-consumer marketing campaigns are actively generating leads and contributing to substantial new patient growth in the U.S., with a 103% increase in new patients in Q4 2025 compared to Q4 2024. The company is also scaling its Eon Care Network, comprising nurses who perform insertion procedures, as a crucial growth driver.
3. International Market Expansion and Regulatory Approvals: Growth is also expected from the expansion of Eversense 365 into new international markets. The company completed its CE Mark application for Eversense 365 in the European Union in Q1 2025, with a launch anticipated in the second half of 2025. The rollout of Eversense 365 outside the United States is a significant factor in the company's financial outlook for 2025 and 2026, with Europe projected to contribute approximately 20% of the full-year 2026 revenue.
4. Integration with Automated Insulin Delivery (AID) Systems: Collaborations to integrate Eversense 365 with automated insulin delivery (AID) systems are expected to drive adoption. Senseonics has a collaboration agreement with Sequel to integrate Eversense 365 with its twiist™ AID system, with a launch expected in Q3 2025. The company has noted encouraging uptake of Eversense 365 in combination with the twiist system. Additionally, a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet® Bionic Pancreas was announced in September 2026.
5. Development and Launch of New Products, such as the Gemini Sensor: Future revenue growth is also tied to the development and anticipated launch of next-generation products. Senseonics secured Investigational Device Exemption (IDE) approval from the FDA to commence a pivotal trial for its self-powered battery-enabled Gemini sensor and has already enrolled the first patients. The 510(k) submission for the Gemini CGM is targeted for Q1 2027, with a launch expected shortly thereafter.

Share Issuance

• Senseonics Holdings conducted a reverse stock split at a ratio of one-for-twenty, which became effective on October 17, 2025, reducing the number of outstanding shares from approximately 816 million to about 41 million.
• The company raised over $20 million in gross proceeds in 2024 and an additional $27.0 million in early 2025 through equity offerings to strengthen its balance sheet.
• In October 2026, directors of Senseonics Holdings, Inc. received common stock in lieu of quarterly cash retainer fees; for example, Edward Fiorentino acquired 1,418 shares, Douglas S. Prince received 1,515 shares, and Steven Edelman was issued 1,292 shares.

Inbound Investments

• In August 2020, Senseonics entered a strategic collaboration and commercialization agreement with Ascensia Diabetes Care, granting Ascensia exclusive worldwide commercial rights to Senseonics products, with Ascensia investing several million dollars in sales and promotion.
• In September 2025, Senseonics and Ascensia signed a memorandum of understanding to transfer the commercial operations related to Eversense back to Senseonics, effective January 1, 2026.

Capital Expenditures

• Senseonics Holdings reported capital expenditures of -$2.17 million over the last 12 months, as of October 9, 2026.
• Quarterly capital expenditures for 2025 included $394,000 in Q4 and $164,000 in Q3, while for 2026, they were $111,000 in Q1 and $217,000 in Q2.
• Research and development expenses, crucial for product development, decreased by $9.5 million in 2025 to $31.6 million, largely due to the completion of Eversense 365 clinical trials; however, higher investment in the Gemini and Freedom development programs contributed to R&D expenses of $11.6 million in Q2 2026.